Traws Pharma Inc (TRAW)

Aug 14, 2026, 4:30 PM EDT - 4 days ago

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Aug 14, 2026, 4:00 PM EDT - 4 days ago

Traws Pharma Quarterly report: Q2 2026

Aug 14, 2026, 4:00 PM EDT - 4 days ago

Traws Pharma Earnings release: Q2 2026

Jul 8, 2026, 9:00 AM EDT - 6 weeks ago

Traws Pharma Transcript: AGM 2026

2026-07-01T20:05:19.000Z - 6 weeks ago

Traws Pharma files $139.19M mixed securities shelf

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Traws Pharma Registration statement: Registration filing

2026-06-22T11:30:46.000Z - 2 months ago

Traws Pharma provides update on tivoxavir marboxil program

Jun 22, 2026, 7:00 AM EDT - 2 months ago

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

2026-06-18T11:27:11.000Z - 2 months ago

Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright

2026-06-15T10:52:38.000Z - 2 months ago

Traws Pharma downgraded to Neutral from Buy at Ladenburg

2026-06-12T21:40:11.000Z - 2 months ago

Traws Pharma influenza challenge study deferred following MHRA review

Jun 12, 2026, 5:30 PM EDT - 2 months ago

Traws Pharma Provides Regulatory Update on Influenza Program

May 29, 2026, 8:00 AM EDT - 2 months ago

Traws Pharma Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Traws Pharma Proxy statement: Proxy filing

2026-05-27T13:04:01.000Z - 3 months ago

Traws Pharma announces antiviral program targeting Hantavirus, Ebola

May 27, 2026, 8:45 AM EDT - 3 months ago

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 19, 2026, 8:00 AM EDT - 3 months ago

Traws Pharma Proxy statement: Proxy filing

May 15, 2026, 7:00 AM EDT - 3 months ago

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 3 months ago

Traws Pharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Traws Pharma Earnings release: Q1 2026

2026-05-08T22:46:20.000Z - 3 months ago

Traws Pharma files to sell 35.9M shares of common stock for holders

May 8, 2026, 1:43 PM EDT - 3 months ago

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

May 8, 2026, 8:00 AM EDT - 3 months ago

Traws Pharma Registration statement: Registration filing

May 8, 2026, 7:30 AM EDT - 3 months ago

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Apr 15, 2026, 4:30 PM EDT - 4 months ago

Traws Pharma Earnings Call Transcript: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 4 months ago

Traws Pharma Earnings release: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 4 months ago

Traws Pharma Annual report: Q4 2025

Apr 15, 2026, 4:01 PM EDT - 4 months ago

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

2026-02-19T12:43:19.000Z - 6 months ago

Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir

Feb 19, 2026, 7:30 AM EST - 6 months ago

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

2026-01-30T12:20:23.000Z - 7 months ago

Traws Pharma initiated with a Buy at Ladenburg

2026-01-26T13:35:09.000Z - 7 months ago

Traws Pharma completes enrollment in Phase 2 study of ratutrelvir

2026-01-13T12:05:30.000Z - 7 months ago

Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

Jan 13, 2026, 7:00 AM EST - 7 months ago

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

2025-12-17T11:11:13.000Z - 8 months ago

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

2025-12-03T11:10:09.000Z - 9 months ago

Traws Pharma initiated with a Buy at H.C. Wainwright

2025-11-13T12:05:59.000Z - 9 months ago

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

Nov 13, 2025, 7:00 AM EST - 9 months ago

Traws Pharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Traws Pharma Earnings release: Q3 2025

Oct 30, 2025, 12:00 PM EDT - 10 months ago

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 22, 2025, 6:40 PM EDT - 10 months ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

2025-10-14T11:10:48.000Z - 11 months ago

Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Traws Pharma Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Traws Pharma Proxy statement: Proxy Filing

2025-10-06T11:37:17.000Z - 11 months ago

Traws Pharma appoints John Leaman as independent director

2025-08-18T11:05:38.000Z - 1 year ago

Traws Pharma receives approval to proceed with Phase 2 COVID studies

Aug 18, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Traws Pharma Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Traws Pharma Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Traws Pharma Quarterly report: Q2 2025

2025-08-14T11:16:52.000Z - 1 year ago

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 8, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jun 30, 2025, 6:30 AM EDT - 1 year ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

May 27, 2025, 8:00 AM EDT - 1 year ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Earnings release: Q1 2025

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings Call Transcript: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Annual report: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings release: Q4 2024

Mar 28, 2025, 4:30 PM EDT - 1 year ago

Traws Pharma Announces Management Updates

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 3, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Feb 28, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 6, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Proxy statement: Proxy Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Proxy statement: Proxy Filing

Jan 23, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 15, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Registration statement: Registration Filing

Jan 10, 2025, 5:55 PM EST - 1 year ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 9:30 AM EST - 1 year ago

Traws Pharma Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Traws Pharma Earnings release: Q3 2024

Oct 11, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Oct 8, 2024, 7:30 AM EDT - 2 years ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Sep 30, 2024, 7:30 AM EDT - 2 years ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 20, 2024, 7:30 AM EDT - 2 years ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 17, 2024, 4:05 PM EDT - 2 years ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Quarterly report: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Earnings release: Q2 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Jul 1, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Registration statement: Registration Filing

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

May 16, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Quarterly report: Q1 2024

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Transcript: M&A Announcement

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Press release: M&A Announcement

Apr 2, 2024, 7:15 AM EDT - 2 years ago

Traws Pharma Announces New Employee Inducement Grants

ONTX

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Annual report: Q4 2023

Mar 8, 2024, 8:00 AM EST - 2 years ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

ONTX

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

ONTX

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

ONTX

Nov 14, 2023, 4:30 PM EST - 3 years ago

Traws Pharma Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Traws Pharma Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Traws Pharma Earnings release: Q3 2023

Nov 14, 2023, 4:05 PM EST - 3 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

ONTX

Nov 7, 2023, 4:05 PM EST - 3 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

ONTX

Nov 2, 2023, 10:37 AM EDT - 3 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

ONTX

Oct 24, 2023, 8:00 AM EDT - 3 years ago

Onconova Expands Leadership Team with Two Key Appointments

ONTX

Oct 19, 2023, 8:00 AM EDT - 3 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

ONTX

Sep 28, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

ONTX

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

ONTX

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Quarterly report: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings release: Q2 2023

Jul 21, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Proxy statement: Proxy Filing

Jun 30, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Registration statement: Registration Filing

Jun 14, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

ONTX